Notably, MLL-AF9 leukemia cells lack the TGF-β1 receptor, suggesting that additional mechanisms are involved in bone remodeling that govern cell expansion.8 More recently, based on the findings indicating disruptive osteogenesis and increased angiogenesis in MDS,9 abaloparatide, a PTH/PTHrP analog, is being tested in combination with bevacizumab (an anti-VEGFA antibody) in a Phase I clinical trial as a treatment for MDS patients (NCT03746041). Here, KMT2A is linked to myelodysplastic syndrome.